We found that patients with low RHBDD1 expression had better RFS or OS times in ER positive breast cancer, ER and PR positive breast cancer, HER2 positive breast cancer, PR positive breast cancer and triple negative breast cancer (the Kaplan–Meier method with log-rank testing, Additional file 3: Figure S1). This evidence concerns the gene ERBB2 and breast carcinoma.